Published in J Intern Med on October 01, 2003
HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol (2011) 6.23
HMGB1: endogenous danger signaling. Mol Med (2008) 4.02
Anti-HMGB1 neutralizing antibody ameliorates gut barrier dysfunction and improves survival after hemorrhagic shock. Mol Med (2006) 2.27
High-mobility group box 1, oxidative stress, and disease. Antioxid Redox Signal (2011) 2.19
HMGB1 in health and disease. Mol Aspects Med (2014) 1.67
Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer. Neoplasia (2009) 1.66
High-mobility group box protein 1 (HMGB1): an alarmin mediating the pathogenesis of rheumatic disease. Arthritis Res Ther (2008) 1.65
Red blood cells induce necroptosis of lung endothelial cells and increase susceptibility to lung inflammation. Am J Respir Crit Care Med (2014) 1.52
Inhibition of the RAGE products increases survival in experimental models of severe sepsis and systemic infection. Crit Care (2007) 1.50
Glycyrrhizin, inhibitor of high mobility group box-1, attenuates monocrotaline-induced pulmonary hypertension and vascular remodeling in rats. Respir Res (2014) 1.45
Biphasic actions of HMGB1 signaling in inflammation and recovery after stroke. Ann N Y Acad Sci (2010) 1.39
Hemorrhagic shock augments lung endothelial cell activation: role of temporal alterations of TLR4 and TLR2. Am J Physiol Regul Integr Comp Physiol (2009) 1.36
Endogenous signals released from necrotic cells augment inflammatory responses to bacterial endotoxin. Immunol Lett (2007) 1.35
Therapeutic potential of HMGB1-targeting agents in sepsis. Expert Rev Mol Med (2008) 1.30
Novel HMGB1-inhibiting therapeutic agents for experimental sepsis. Shock (2009) 1.29
Inhibition of reactive astrocytes with fluorocitrate retards neurovascular remodeling and recovery after focal cerebral ischemia in mice. J Cereb Blood Flow Metab (2009) 1.27
High mobility group box protein 1 in complex with lipopolysaccharide or IL-1 promotes an increased inflammatory phenotype in synovial fibroblasts. Arthritis Res Ther (2011) 1.27
Role of HMGB1 in cardiovascular diseases. Curr Opin Pharmacol (2006) 1.26
HMGB1 induces human lung endothelial cell cytoskeletal rearrangement and barrier disruption. Microvasc Res (2010) 1.24
Astrocytic high-mobility group box 1 promotes endothelial progenitor cell-mediated neurovascular remodeling during stroke recovery. Proc Natl Acad Sci U S A (2012) 1.24
Lipopolysaccharide activates Toll-like receptor 4 (TLR4)-mediated NF-κB signaling pathway and proinflammatory response in human pericytes. J Biol Chem (2013) 1.23
Activated protein C inhibits high mobility group box 1 signaling in endothelial cells. Blood (2011) 1.22
Regulation of osteoclast function and bone mass by RAGE. J Exp Med (2006) 1.21
High Mobility Group Box Protein-1 correlates with renal function in chronic kidney disease (CKD). Mol Med (2008) 1.17
Renal expression and serum levels of high mobility group box 1 protein in lupus nephritis. Arthritis Res Ther (2012) 1.17
Bench-to-bedside review: High-mobility group box 1 and critical illness. Crit Care (2007) 1.14
High-mobility group box-1 and biomarkers of inflammation in the vitreous from patients with proliferative diabetic retinopathy. Mol Vis (2011) 1.10
Role of ERK map kinase and CRM1 in IL-1beta-stimulated release of HMGB1 from cortical astrocytes. Glia (2010) 1.09
HMGB1 in renal ischemic injury. Am J Physiol Renal Physiol (2012) 1.07
High-mobility group box-1 protein (HMGB1) is increased in antineutrophilic cytoplasmatic antibody (ANCA)-associated vasculitis with renal manifestations. Mol Med (2010) 1.04
Role of inflammation in the pathogenesis of diabetic retinopathy. Middle East Afr J Ophthalmol (2012) 1.04
HMGB1 cytoplasmic translocation in patients with acute liver failure. BMC Gastroenterol (2011) 1.04
Beyond tissue injury-damage-associated molecular patterns, toll-like receptors, and inflammasomes also drive regeneration and fibrosis. J Am Soc Nephrol (2014) 1.03
HMGB1 increases permeability of the endothelial cell monolayer via RAGE and Src family tyrosine kinase pathways. Inflammation (2012) 1.02
HMGB1, an innate alarmin, in the pathogenesis of type 1 diabetes. Int J Clin Exp Pathol (2009) 1.00
Targeting HMGB1 in the treatment of sepsis. Expert Opin Ther Targets (2014) 0.99
PF-04494700, an oral inhibitor of receptor for advanced glycation end products (RAGE), in Alzheimer disease. Alzheimer Dis Assoc Disord (2011) 0.99
Astrocytes, therapeutic targets for neuroprotection and neurorestoration in ischemic stroke. Prog Neurobiol (2015) 0.99
Potential role of high mobility group box 1 in viral infectious diseases. Viral Immunol (2006) 0.98
Anti-inflammatory role of fetuin-A in injury and infection. Curr Mol Med (2012) 0.96
Prolonged neuroinflammation after lipopolysaccharide exposure in aged rats. PLoS One (2014) 0.94
Cardiac nuclear high mobility group box 1 prevents the development of cardiac hypertrophy and heart failure. Cardiovasc Res (2013) 0.93
High mobility group box 1 protein as a potential drug target for infection- and injury-elicited inflammation. Inflamm Allergy Drug Targets (2010) 0.92
High-mobility group box-1 and endothelial cell angiogenic markers in the vitreous from patients with proliferative diabetic retinopathy. Mediators Inflamm (2012) 0.91
Osteopontin and other regulators of angiogenesis and fibrogenesis in the vitreous from patients with proliferative vitreoretinal disorders. Mediators Inflamm (2012) 0.90
HMGB1, IL-1α, IL-33 and S100 proteins: dual-function alarmins. Cell Mol Immunol (2016) 0.89
MiR-129-2 functions as a tumor suppressor in glioma cells by targeting HMGB1 and is down-regulated by DNA methylation. Mol Cell Biochem (2015) 0.89
High-mobility group box-1 induces decreased brain-derived neurotrophic factor-mediated neuroprotection in the diabetic retina. Mediators Inflamm (2013) 0.89
High mobility group box 1 is a novel substrate of dipeptidyl peptidase-IV. Diabetologia (2011) 0.88
Ambient particulate air pollution and microRNAs in elderly men. Epidemiology (2014) 0.88
High-mobility group box 1 from reactive astrocytes enhances the accumulation of endothelial progenitor cells in damaged white matter. J Neurochem (2012) 0.87
Ethyl pyruvate inhibits retinal pathogenic neovascularization by downregulating HMGB1 expression. J Diabetes Res (2013) 0.87
Thrombin inhibits HMGB1-mediated proinflammatory signaling responses when endothelial protein C receptor is occupied by its natural ligand. BMB Rep (2013) 0.85
The role of cell death in the pathogenesis of autoimmune disease: HMGB1 and microparticles as intercellular mediators of inflammation. Mod Rheumatol (2008) 0.85
Novel Mechanisms of Herbal Therapies for Inhibiting HMGB1 Secretion or Action. Evid Based Complement Alternat Med (2015) 0.84
Knockdown of HMGB1 improves apoptosis and suppresses proliferation and invasion of glioma cells. Chin J Cancer Res (2014) 0.83
A simple method for establishing adherent ex vivo explant cultures from human eye pathologies for use in subsequent calcium imaging and inflammatory studies. J Immunol Res (2014) 0.82
Intravenous ascorbic acid to prevent and treat cancer-associated sepsis? J Transl Med (2011) 0.81
High mobility group box 1 protein induction by Mycobacterium bovis BCG. Mediators Inflamm (2007) 0.81
Effects of lower concentration thrombin on high-mobility group box 1 protein-mediated inflammatory responses. Inflammation (2012) 0.81
Instigation of endothelial Nlrp3 inflammasome by adipokine visfatin promotes inter-endothelial junction disruption: role of HMGB1. J Cell Mol Med (2015) 0.80
High-mobility group box 1: an amplifier of stem and progenitor cell activity after stroke. Acta Neurochir Suppl (2013) 0.80
The proinflammatory cytokine high-mobility group box-1 mediates retinal neuropathy induced by diabetes. Mediators Inflamm (2014) 0.79
Caging a Beast in the Inflammation Arena: Use of Chinese Medicinal Herbs to Inhibit a Late Mediator of Lethal Sepsis, HMGB1. Int J Clin Exp Med (2008) 0.78
High-mobility-group box chromosomal protein 1 as a new target for modulating stress response. Surg Today (2010) 0.77
Disruption of a Regulatory Network Consisting of Neutrophils and Platelets Fosters Persisting Inflammation in Rheumatic Diseases. Front Immunol (2016) 0.77
Treatment of severe sepsis: where next? Current and future treatment approaches after the introduction of drotrecogin alfa. Vasc Health Risk Manag (2006) 0.77
Anti-septic effects of pellitorine in HMGB1-induced inflammatory responses in vitro and in vivo. Inflammation (2014) 0.77
LPS-Primed Release of HMGB-1 from Cortical Astrocytes is Modulated Through PI3K/AKT Pathway. Cell Mol Neurobiol (2015) 0.77
Repeated intratracheal instillation of PM10 induces lipid reshaping in lung parenchyma and in extra-pulmonary tissues. PLoS One (2014) 0.76
Elevated levels of high-mobility group box-1 (HMGB1) in patients with severe or uncomplicated Plasmodium falciparum malaria. Am J Trop Med Hyg (2013) 0.76
Toll-like receptor 4 signaling: A common pathway for interactions between prooxidants and extracellular disulfide high mobility group box 1 (HMGB1) protein-coupled activation. Biochem Pharmacol (2015) 0.76
High-mobility group box 1 inhibits HCO3- absorption in medullary thick ascending limb through a basolateral receptor for advanced glycation end products pathway. Am J Physiol Renal Physiol (2015) 0.76
Prognostic value of the high-mobility group box-1 in young patients with chest pain. ARYA Atheroscler (2014) 0.76
RAGE Expression and ROS Generation in Neurons: Differentiation versus Damage. Oxid Med Cell Longev (2016) 0.76
High Mobility Group Box Protein 1 Boosts Endothelial Albumin Transcytosis through the RAGE/Src/Caveolin-1 Pathway. Sci Rep (2016) 0.75
The Role of HMGB1 in the Pathogenesis of Type 2 Diabetes. J Diabetes Res (2016) 0.75
Pathophysiology of Endometriosis: Role of High Mobility Group Box-1 and Toll-Like Receptor 4 Developing Inflammation in Endometrium. PLoS One (2016) 0.75
The Expression of HMGB1 in Bone Marrow MSCs Is Upregulated by Hypoxia with Regulatory Effects on the Apoptosis and Adhesion. Biomed Res Int (2016) 0.75
Intratracheal instillation of ethyl pyruvate nanoparticles prevents the development of shunt-flow-induced pulmonary arterial hypertension in a rat model. Int J Nanomedicine (2016) 0.75
High-mobility group box-1 protein serum levels do not reflect monocytic function in patients with sepsis-induced immunosuppression. Mediators Inflamm (2010) 0.75
Ethanol extracts from Portulaca oleracea L. attenuated ischemia/reperfusion induced rat neural injury through inhibition of HMGB1 induced inflammation. Am J Transl Res (2016) 0.75
NETosis in Alzheimer's Disease. Front Immunol (2017) 0.75
Response of the cerebral vasculature following traumatic brain injury. J Cereb Blood Flow Metab (2017) 0.75
Pivotal neuroinflammatory and therapeutic role of high mobility group box 1 in ischemic stroke. Biosci Rep (2017) 0.75
Initial sequencing and analysis of the human genome. Nature (2001) 212.86
HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science (2001) 22.06
Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell (1999) 19.48
HMG-1 as a late mediator of endotoxin lethality in mice. Science (1999) 17.72
Shock and tissue injury induced by recombinant human cachectin. Science (1986) 16.24
Health information on the Internet: accessibility, quality, and readability in English and Spanish. JAMA (2001) 15.23
Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature (2000) 11.49
High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med (2000) 7.38
Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association. Cell (1999) 6.59
Mitogens as probes for immunocyte activation and cellular cooperation. Transplant Rev (1972) 5.66
MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature (1993) 5.60
Regulation of flowering time by Arabidopsis photoreceptors. Science (1998) 5.11
VPS27 controls vacuolar and endocytic traffic through a prevacuolar compartment in Saccharomyces cerevisiae. J Cell Biol (1995) 5.04
Selective induction of DNA synthesis in T and B lymphocytes. Cell Immunol (1972) 4.94
HMG-1 as a mediator of acute lung inflammation. J Immunol (2000) 4.78
The mitogenic effect of lipopolysaccharide on bone marrow-derived mouse lymphocytes. Lipid A as the mitogenic part of the molecule. J Exp Med (1973) 4.74
Antibodies to cachectin/tumor necrosis factor reduce interleukin 1 beta and interleukin 6 appearance during lethal bacteremia. J Exp Med (1989) 4.66
Induction of immunoglobulin and antibody synthesis in vitro by lipopolysaccharides. Eur J Immunol (1972) 4.64
Neuraxial block, death and serious cardiovascular morbidity in the POISE trial. Br J Anaesth (2013) 4.60
A new highly penetrant form of obesity due to deletions on chromosome 16p11.2. Nature (2010) 4.52
Cachectin/tumor necrosis factor induces lethal shock and stress hormone responses in the dog. Surg Gynecol Obstet (1987) 4.18
The SCID but not the RAG-2 gene product is required for S mu-S epsilon heavy chain class switching. Immunity (1996) 4.02
Activation of EGFP expression by Cre-mediated excision in a new ROSA26 reporter mouse strain. Blood (2001) 3.93
Crystal structure of a Smad MH1 domain bound to DNA: insights on DNA binding in TGF-beta signaling. Cell (1998) 3.86
Structure-activity analysis of synthetic autoinducing thiolactone peptides from Staphylococcus aureus responsible for virulence. Proc Natl Acad Sci U S A (1999) 3.79
Increased production of IL-7 accompanies HIV-1-mediated T-cell depletion: implications for T-cell homeostasis. Nat Med (2001) 3.69
Rhabdomyolysis. Intern Emerg Med (2007) 3.56
Strategies of anti-cytokine monoclonal antibody development: immunoassay of IL-10 and IL-5 in clinical samples. Immunol Rev (1992) 3.42
Enhancement of blue-light sensitivity of Arabidopsis seedlings by a blue light receptor cryptochrome 2. Proc Natl Acad Sci U S A (1998) 3.34
Cytokine appearance in human endotoxemia and primate bacteremia. Surg Gynecol Obstet (1988) 3.30
Clonal growth and maturation to immunoglobulin secretion in vitro of every growth-inducible B lymphocyte. Cell (1977) 3.23
Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis (1999) 3.21
Assessment of cytokines by immunofluorescence and the paraformaldehyde-saponin procedure. Immunol Rev (1991) 3.08
T-cell-dependent B-cell stimulation is H-2 restricted and antigen dependent only at the resting B-cell level. Proc Natl Acad Sci U S A (1980) 3.08
Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup. Gastroenterology (1996) 3.08
A functional interleukin 12 receptor complex is composed of two beta-type cytokine receptor subunits. Proc Natl Acad Sci U S A (1996) 3.07
Adipose cell hyperplasia and enhanced glucose disposal in transgenic mice overexpressing GLUT4 selectively in adipose tissue. J Biol Chem (1993) 3.02
Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest (1991) 3.00
RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages. Scand J Immunol (2005) 2.96
Extracellular role of HMGB1 in inflammation and sepsis. J Intern Med (2004) 2.94
HMGB1 release and redox regulates autophagy and apoptosis in cancer cells. Oncogene (2010) 2.91
Does oxidative damage to DNA increase with age? Proc Natl Acad Sci U S A (2001) 2.91
Fungi isolated from tobacco leaves and brown-spot lesions before and after flue-curing. Appl Microbiol (1968) 2.87
Selective cytokine production by epithelial cells following exposure to Escherichia coli. Infect Immun (1993) 2.83
HMGB1 as a late mediator of lethal systemic inflammation. Am J Respir Crit Care Med (2001) 2.80
von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hum Mol Genet (2001) 2.79
Antagonistic actions of Arabidopsis cryptochromes and phytochrome B in the regulation of floral induction. Development (1999) 2.76
Familial expression of anti-Saccharomyces cerevisiae mannan antibodies in affected and unaffected relatives of patients with Crohn's disease. Gut (2000) 2.71
Frequencies of mitogen-reactive B cells in the mouse. I. Distribution in different lymphoid organs from different inbred strains of mice at different ages. J Exp Med (1977) 2.68
Macrophage inflammatory protein 1 modulates macrophage function. J Immunol (1992) 2.66
Studies on T lymphocyte activation. I. Requirements for the mitogen-dependent production of T cell growth factors. Eur J Immunol (1979) 2.59
Lipopolysaccharide can substitute for helper cells in the antibody response in vitro. Eur J Immunol (1972) 2.58
Characterization of a new subfamily of winged-helix/forkhead (Fox) genes that are expressed in the lung and act as transcriptional repressors. J Biol Chem (2001) 2.57
Monoclonal T-cell proliferation and plaque instability in acute coronary syndromes. Circulation (2000) 2.56
A "knockdown" mutation created by cis-element gene targeting reveals the dependence of erythroid cell maturation on the level of transcription factor GATA-1. Proc Natl Acad Sci U S A (1997) 2.55
Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics. Gut (2000) 2.47
High mobility group box chromosomal protein 1: a novel proinflammatory mediator in synovitis. Arthritis Rheum (2002) 2.45
Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures. Neurology (2012) 2.45
Proinflammatory cytokines (tumor necrosis factor and interleukin 1) stimulate release of high mobility group protein-1 by pituicytes. Surgery (1999) 2.44
Activation of B lymphocytes by locally concentrated concanavalin A. Eur J Immunol (1972) 2.41
The product of the pleiotropic Escherichia coli gene csrA modulates glycogen biosynthesis via effects on mRNA stability. J Bacteriol (1995) 2.40
Repertoire of chemokine receptor expression in the female genital tract: implications for human immunodeficiency virus transmission. Am J Pathol (1998) 2.38
Establishing human prostate cancer cell xenografts in bone: induction of osteoblastic reaction by prostate-specific antigen-producing tumors in athymic and SCID/bg mice using LNCaP and lineage-derived metastatic sublines. Int J Cancer (1998) 2.36
Inhibition of mitogenic stimulation of mouse lymphocytes by anti-mouse immunoglobulin antibodies. I. Mode of action. Eur J Immunol (1974) 2.33
Superior ex vivo cord blood expansion following co-culture with bone marrow-derived mesenchymal stem cells. Bone Marrow Transplant (2006) 2.29
Myc requires distinct E2F activities to induce S phase and apoptosis. Mol Cell (2001) 2.29
Successful treatment of collagen-induced arthritis in mice and rats by targeting extracellular high mobility group box chromosomal protein 1 activity. Arthritis Rheum (2003) 2.26
Reduced mRNA abundance of the main enzymes involved in methionine metabolism in human liver cirrhosis and hepatocellular carcinoma. J Hepatol (2000) 2.22
Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. J Viral Hepat (2008) 2.19
CD8(+) T-cell selection, function, and death in the primary immune response in vivo. J Clin Invest (2000) 2.19
An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. Gastroenterology (1999) 2.16
Synthesis, surface deposition and secretion of immunoglobulin M in bone marrow-derived lymphocytes before and after mitogenic stimulation. Transplant Rev (1973) 2.14
Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC). J Virol (2001) 2.14
Dressed to kill? A review of why antiviral CD8 T lymphocytes fail to prevent progressive immunodeficiency in HIV-1 infection. Blood (2001) 2.13
Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology (1998) 2.12
Cholinergic control of inflammation. J Intern Med (2009) 2.12
Inhibition of nuclear hormone receptor activity by calreticulin. Nature (1994) 2.11
Isolation of high-affinity peptide antagonists of 14-3-3 proteins by phage display. Biochemistry (1999) 2.10
Studies on T lymphocyte activation II. The target cells for concanavalin A-induced growth factors. Eur J Immunol (1979) 2.10
Pleiotropic regulation of central carbohydrate metabolism in Escherichia coli via the gene csrA. J Biol Chem (1995) 2.10
The pulse of inflammation: heart rate variability, the cholinergic anti-inflammatory pathway and implications for therapy. J Intern Med (2011) 2.08
Role of vagus nerve signaling in CNI-1493-mediated suppression of acute inflammation. Auton Neurosci (2000) 2.06
Stabilization and productive positioning roles of the C2 domain of PTEN tumor suppressor. Cancer Res (2000) 2.02
Cachectin/TNF or IL-1 alpha induces cachexia with redistribution of body proteins. Am J Physiol (1989) 1.99